Published in Cancer Res on September 15, 2007
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. Cell (2016) 1.57
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol (2011) 1.36
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res (2010) 1.24
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst) (2014) 1.17
A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells. Biochemistry (2010) 1.12
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination. Proc Natl Acad Sci U S A (2009) 1.10
DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus. Nucleic Acids Res (2009) 1.09
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat Rev Mol Cell Biol (2016) 1.05
Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Res (2008) 1.00
Resistant starches protect against colonic DNA damage and alter microbiota and gene expression in rats fed a Western diet. J Nutr (2012) 1.00
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther (2011) 0.98
Antisense transcripts enhanced by camptothecin at divergent CpG-island promoters associated with bursts of topoisomerase I-DNA cleavage complex and R-loop formation. Nucleic Acids Res (2013) 0.91
DNA break mapping reveals topoisomerase II activity genome-wide. Int J Mol Sci (2014) 0.91
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One (2012) 0.89
Cathepsin E is a marker of gastric differentiation and signet-ring cell carcinoma of stomach: a novel suggestion on gastric tumorigenesis. PLoS One (2013) 0.88
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation. Proc Natl Acad Sci U S A (2011) 0.87
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther (2011) 0.86
The DNA repair endonuclease Mus81 facilitates fast DNA replication in the absence of exogenous damage. Nat Commun (2015) 0.86
Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases IIα and IIβ in vertebrate mitochondria. Nucleic Acids Res (2014) 0.85
Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Rep (2013) 0.84
Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB. Bioorg Chem (2008) 0.83
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability. Nat Commun (2016) 0.81
The SR protein B52/SRp55 is required for DNA topoisomerase I recruitment to chromatin, mRNA release and transcription shutdown. PLoS Genet (2010) 0.81
Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission. J Biol Chem (2008) 0.80
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer (2016) 0.79
Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts. Arthritis Res Ther (2011) 0.78
Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line. Cancer Biol Ther (2012) 0.78
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem (2014) 0.78
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors. BMC Cancer (2014) 0.78
Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines. Oncol Rep (2013) 0.77
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorg Med Chem Lett (2009) 0.76
Topoisomerase 3β is the major topoisomerase for mRNAs and linked to neurodevelopment and mental dysfunction. Nucleic Acids Res (2017) 0.75
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res (2016) 0.75
Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning. J Transl Med (2017) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
The marine viromes of four oceanic regions. PLoS Biol (2006) 10.19
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
Epidermal electronics. Science (2011) 8.65
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol (2004) 4.87
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
Metagenomic analysis of the microbial community associated with the coral Porites astreoides. Environ Microbiol (2007) 4.21
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Pluripotent stem cells from the adult mouse inner ear. Nat Med (2003) 3.92
Perioperative dexmedetomidine improves outcomes of cardiac surgery. Circulation (2013) 3.91
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry (2002) 3.47
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 3.46
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04
Preoperative aspirin use and outcomes in cardiac surgery patients. Ann Surg (2012) 3.03
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
Viral and microbial community dynamics in four aquatic environments. ISME J (2010) 2.95
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
A survey on gas sensing technology. Sensors (Basel) (2012) 2.79
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Biodiversity and biogeography of phages in modern stromatolites and thrombolites. Nature (2008) 2.70
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem (2005) 2.64
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
Sodium-calcium exchange initiated by the Ca2+ transient: an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol (2006) 2.57
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum (2004) 2.48
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011). Chem Rev (2013) 2.38
Three microarray platforms: an analysis of their concordance in profiling gene expression. BMC Genomics (2005) 2.29
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood (2003) 2.26
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity (2013) 2.20
The human beta-globin locus control region can silence as well as activate gene expression. Mol Cell Biol (2005) 2.19
Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney Int (2009) 2.19
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int (2012) 2.12
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain (2005) 2.10
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10